March 12, 2019Open Access

Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Empagliflozin appeared safe and improved glycemic control in renal transplant recipients with PTDM compared with placebo. A concomitant reduction in body weight was seen.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Halden et al. (Tue,) studied this question.

synapsesocial.com/papers/69dbc63b50e1971baba3ca0b https://doi.org/https://doi.org/10.2337/dc19-0093

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Executive Summary: Standards of Medical Care in Diabetes—20122011 · 292 citations
2Simple Measures to Monitor b -Cell Mass and Assess Islet Graft Dysfunction2006 · 95 citations
3New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation2005 · 392 citations
4Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin2017 · 245 citations
5GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes2016 · 67 citations

Me gusta

Guardar

Ver artículo completo